Cited by 55Proteoglycans and glycosaminoglycans researchNeurogenesis and neuroplasticity mechanismsOsteoarthritis Treatment and Mechanisms

Localization of aggrecan and versican in the developing rat central nervous system.

Open access
Popp, Susanna, Andersen, Julie S., Maurel, Patrice, Margolis, Richard U.·2003·Developmental Dynamics

Abstract

The localization of aggrecan and mRNA splice variants of versican in the developing rat central nervous system has been examined by using specific polyclonal antibodies to the nonhomologous glycosaminoglycan attachment regions of these hyaluronan‐binding chondroitin sulfate proteoglycans. At embryonic day 16 (E16), aggrecan and versican splice variants containing either or both the α‐and β‐domains are present in the marginal zone and subplate of the cerebral cortex and in the amygdala, internal capsule, and the optic and lateral olfactory tracts. There is strong staining of versican but not of aggrecan in the hippocampus and dentate gyrus by E19, whereas both aggrecan and α‐versican are present in the fimbria. At E19, aggrecan is seen throughout the cerebral cortex, whereas the distribution of versican is considerably more limited, being confined essentially to the marginal zone and subplate. At 1 week postnatal, both aggrecan and versican are present in the prospective white matter and in the molecular and granule cell layers of the cerebellum, but neither proteoglycan is seen in the external granule cell layer. α‐ but not β‐versican staining is seen in Purkinje cells, and aggrecan staining of Purkinje cells is also rather minimal. In the spinal cord at E13, aggrecan is present in the dorsal root entry zone, ventral funiculus, mantle layer, and floor plate, as well as in the dorsal root ganglia and ventral roots. However, α‐versican is confined to the dorsal root entry zone and the ependyma surrounding the spinal canal, and β‐versican is not present in spinal cord parenchyma at this developmental stage, being limited to the surrounding connective tissue. By E19, there are significant amounts of all three proteoglycans in the spinal cord. Aggrecan staining is most intense in the lateral funiculus and the fasciculi gracilis and cuneatus, where α‐versican staining is also strong. In contrast, β‐versican is seen predominantly in the motor columns. Differences in the localization and temporal expression patterns of these chondroitin sulfate proteoglycans suggest that, like neurocan and phosphacan, they have partially complementary roles during central nervous system development. Development Dynamics 227:143–149, 2003. © 2003 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dvdy.10282

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Popp, S., Andersen, J. S., Maurel, P., & Margolis, R. U.
Affiliations
NYU Langone Health (US)
Corresponding author
Margolis, Richard U.
Venue
Developmental Dynamics
Publisher
Wiley
Published
2003-03-12
Volume
227
Issue
1
Pages
143-149
ISSN
  • 1058-8388 (ISSN-L)
  • 1097-0177
OpenAlex
W2087503703
Cited by
55
References
26
Citations by year
2024: 3 · 2022: 3 · 2020: 5 · 2019: 1 · 2018: 4 · 2016: 1 · 2015: 3 · 2014: 2 · 2013: 1
FWCI
1.82
Type
journal article
Language
en
Open access
Locations
  • Developmental Dynamics (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS009348, NS-09348, R01NS013876, NS 13876)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
Keywords
aggrecan, versican, chondroitin sulfate proteoglycans, central nervous system development, splice variants, cerebral cortex, cerebellum, spinal cord, Purkinje cells, marginal zone, subplate, neurocan, phosphacan
MeSH terms
Animals, Central Nervous System, Embryo, Mammalian, Immunohistochemistry, Chondroitin Sulfate Proteoglycans, Proteoglycans, Extracellular Matrix Proteins, Protein Structure, Tertiary, Protein Isoforms, Lectins, C-Type, Rats, Aggrecans, Versicans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review